tiprankstipranks
CytoTools AG (DE:T5O)
XETRA:T5O
Germany Market

CytoTools AG (T5O) Income Statement

0 Followers

CytoTools AG Income Statement

Last quarter (Q ), CytoTools AG's total revenue was €―, a decrease of ― from the same quarter last year. In Q, CytoTools AG's net income was €―. See CytoTools AG’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 21Dec 20Dec 19Dec 18Dec 17
Total Revenue
-€ 44.63K€ 36.00K€ 36.18K€ 1.01K€ 89.82K
Cost of Revenue
-€ 540.65K€ 748.31K€ 309.95K€ 426.13K€ 392.52K
Gross Profit
-€ -496.02K€ -712.31K€ -273.77K€ -425.11K€ 3.60K
Operating Expense
-€ 1.57M€ 1.13M€ 900.69K€ 797.92K€ 714.45K
Operating Income
-€ -1.53M€ -1.84M€ -1.17M€ -1.22M€ -1.02M
Net Non Operating Interest Income Expense
-€ -172.26€ -611.70€ -99.72K€ -198.08K€ -46.81K
Other Income Expense
------
Pretax Income
-€ -4.02M€ -1.84M€ -1.27M€ -1.42M€ -1.06M
Tax Provision
-€ 40.30K€ 429.89€ 424.00€ 474.83€ 418.00
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-€ -4.06M€ -1.84M€ -1.27M€ -1.42M€ -1.07M
Basic EPS
-€ -0.98€ -0.44€ -0.35€ -0.53€ -0.50
Diluted EPS
-€ -0.98€ -0.44€ -0.35€ -0.53€ -0.50
Basic Average Shares
-€ 4.15M€ 4.15M€ 3.66M€ 2.69M€ 2.12M
Diluted Average Shares
-€ 4.15M€ 4.15M€ 3.66M€ 2.69M€ 2.12M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
-€ 1.57M€ 1.87M€ 1.21M€ 1.22M€ 1.11M
Net Income From Continuing And Discontinued Operation
-€ -4.06M€ -1.84M€ -1.27M€ -1.42M€ -1.07M
Normalized Income
-€ -2.32M€ -1.84M€ -1.27M€ -1.42M€ -1.07M
Interest Expense
-€ 2.12K€ 776.24€ 99.72K€ 251.09K€ 59.08K
EBIT
-€ -4.02M€ -1.84M€ -1.17M€ -1.17M€ -1.01M
EBITDA
-€ -1.47M€ -1.82M€ -1.16M€ -1.14M€ -970.10K
Currency in EUR

CytoTools AG Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis